Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 7—July 2020
Research

Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013–2018

Pieter P.A. Lestrade, Jochem B. Buil, Martha T. van der Beek, Ed J. Kuijper, Karin van Dijk, Greetje A. Kampinga, Bart J.A. Rijnders, Alieke G. Vonk, Sabine C. de Greeff, Annelot F. Schoffelen, Jaap van Dissel, Jacques F. Meis, Willem J.G. Melchers, Paul E. VerweijComments to Author , and Kuijper
Author affiliations: VieCuri Hospital, Venlo, the Netherlands (P.P.A. Lestrade); Center of Expertise in Mycology Radboud University Medical Center/Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands (J.B. Buil, J.F. Meis, W.J.G. Melchers, P.E. Verweij); Leiden University Medical Center, Leiden, the Netherlands (M.T. van der Beek, E.J. Kuijper); Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (K. van Dijk); University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (G.A. Kampinga); Erasmus Medical Center, Rotterdam, the Netherlands (B.J.A. Rijnders, A.G. Vonk); Center for Infectious Disease Control, Dutch National Institute for Public Health and the Environment, Bilthoven, the Netherlands (S.C. de Greeff, A.F. Schoffelen, J. van Dissel)

Main Article

Figure 2

Triazole-resistance classification in 555 Aspergillus fumigatus isolates harboring TR34/L98H and TR46/Y121F/T289A resistance mutations, as observed in a national multicenter surveillance program in the Netherlands, 2013–2018. A) Itraconazole TR34/L98H. B) Voriconazole TR34/L98H. C) Posaconazole TR34/L98H. D) Isavuconazole TR34/L98H. E) Itraconazole TR46/Y121F/T289A. F) Voriconazole, TR46/Y121F/T289A. G) Posaconazole TR46/Y121F/T289A. H) Isavuconazole TR46/Y121F/T289A. I, intermediate; R, resista

Figure 2. Triazole-resistance classification in 555 Aspergillus fumigatus isolates harboring TR34/L98H and TR46/Y121F/T289A resistance mutations, as observed in a national multicenter surveillance program in the Netherlands, 2013–2018. A) Itraconazole TR34/L98H. B) Voriconazole TR34/L98H. C) Posaconazole TR34/L98H. D) Isavuconazole TR34/L98H. E) Itraconazole TR46/Y121F/T289A. F) Voriconazole, TR46/Y121F/T289A. G) Posaconazole TR46/Y121F/T289A. H) Isavuconazole TR46/Y121F/T289A. I, intermediate; R, resistant; S, susceptible.

Main Article

Page created: May 05, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external